November 18, 2025 — Leads & Copy — MediciNova, Inc. (NASDAQ:MNOV) has appointed Dr. Christopher D. Breder, MD, PhD, as Clinical and Regulatory Advisor to provide strategic guidance for drug development programs and lead the Scientific Advisory Board once formed.
Dr. Breder is a physician-scientist and regulatory expert with over two decades of experience at the U.S. Food and Drug Administration (FDA) and major pharmaceutical companies. During his time at the FDA, he served as Medical Officer and Lead Medical Officer and developed and taught NDA review and safety analysis courses for FDA reviewers. He also played a key role in the review and initial approvals of therapies for neurological conditions, including Amyotrophic Lateral Sclerosis (ALS), Myasthenia Gravis (MG), and Duchenne’s Muscular Dystrophy (DMD).
More recently, Dr. Breder contributed as an industry advisor to another ALS drug approval in 2022.
According to MediciNova, Dr. Breder’s dual perspective provides expertise in clinical trial design, regulatory strategy, and the development of novel therapies in neuroscience and rare diseases. His experience will assist MediciNova in advancing its pipeline and navigating regulatory pathways. He holds an M.D. and a Ph.D. from the University of Chicago and completed his clinical training at The Johns Hopkins Hospital.
MediciNova President and CEO Dr. Yuichi Iwaki said the company is honored to welcome Dr. Breder to the team and added that his understanding of FDA processes and track record in ALS and other neurological disorders will be invaluable as the company accelerates its mission to deliver transformative therapies to patients.
Dr. Breder said that he aims to accelerate meaningful outcomes for innovative solutions for neurodegenerative diseases by combining rigorous science with patient-centered design.
MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Its lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-001 (tipelukast) is in a Phase 2 trial treating hypertriglycedemia in type 2 diabetic patients.
Contact:
David H. Crean, Ph.D.
Chief Business Officer
MediciNova, Inc
info@medicinova.com
Source: MediciNova, Inc.
